This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
BMS’ PD-L1 inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients. ... The European Medicines Agency (EMA) has already validated the completion of
The US Food and Drug Administration (FDA) has accepted a priority review for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) plus chemotherapy combination in stomach cancer. ... Although Opdivo lags behind Keytruda, BMS has been aiming for a number of
Aside from KY1005, Kymab’s pipeline also includes an early-stage oncology candidate – KY1044 – which is currently being investigated as a monotherapy treatment and in combination with a PD-L1 inhibitor. ... The Kymab acquisition adds KY1005 to our
The BTD covers the combination treatment in the first-line setting for people with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR ... Results from this study showed that, after an average follow-up of
The new combination treatment, containing Herceptin (trastuzumab) and Perjeta (pertuzumab) with hyaluronidase, has been authorised for use for the treatment of early and metastatic HER2-positive breast cancer. ... This means that the combination
Drug approved for emergency use in combination with Gilead's remdesivir. Eli Lilly and Incyte’s arthritis treatment baricitinib has been repurposed as a COVID-19 treatment, scoring an emergency use ... The EUA covers baricitinib in combination with
More from news
Approximately 0 fully matching, plus 287 partially matching documents found.
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business
And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...